{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:20:56Z","timestamp":1759332056892,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Malignant mesothelioma (MM) is a highly aggressive cancer with a poor prognosis. Despite the use of several well-known markers, the diagnosis of MM is still challenging in some cases. we applied bioinformatics to identify key genes and screen for diagnostic and prognostic markers of MM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The expression profiles of GSE2549 and GSE112154 microarray datasets from the Gene Expression Omnibus database contained 87 cases of MM tissue and 8 cases of normal mesothelial tissue in total. The GEO2R tool was used to detect differentially expressed genes (DEGs). Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of DEGs were performed using DAVID Bioinformatics Resources. The DEGs protein-protein interaction networks were constructed from the STRING database. Cytoscape was used to identify significant modules and hub genes. The GEPIA database was used to explore relationships between hub genes and prognosis of MM. Immunohistochemistry was used to analyze protein expression in tissue microarrays with 47 Chinese MM tissues. Statistical analyses diagnostic and prognostic values.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>346 DEGs were identified: 111 genes upregulated, and 235 downregulated. GO analysis showed that the primary biological processes of these DEGs were cell adhesion, leukocyte migration, and angiogenesis. The main cellular components included the extracellular space, extracellular exosome, and extracellular region. The molecular functions were integrin binding, heparin binding, and calcium ion binding. KEGG pathway analysis showed that DEGs are primarily involved in PPAR signaling pathway, extracellular matrix\u2013receptor interactions, and regulation of lipolysis in adipocytes. Survival analysis showed that seven genes\u2014<jats:italic>AURKA, GAPDH, TOP2A, PPARG, SCD, FABP4<\/jats:italic>, and <jats:italic>CEBPA<\/jats:italic>\u2014may be potential prognostic markers for MM. Immunohistochemical studies showed that Aurora kinase A (<jats:italic>AURKA<\/jats:italic> gene encode, Aurora-A) and GAPDH were highly expressed in MM tissue in comparison with normal mesothelial tissue. Kaplan-Meier analysis confirmed a correlation between Aurora-A protein expression and overall survival but did not confirm a correlation with GAPDH. The receiver operating characteristic curves of Aurora-A protein expression suggested acceptable accuracy (AUC\u00a0=\u00a00.827; 95%\u00a0CI [0.6686 to 0.9535]; <jats:italic>p\u00a0<\/jats:italic>=\u00a00.04). The sensitivity and specificity of Aurora-A were 83.33% and 77.78%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Aurora-A could be an optimal diagnostic biomarker and a potential prognostic marker for MM.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.789244","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T05:30:10Z","timestamp":1638941410000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Aurora Kinase A as a Diagnostic and Prognostic Marker of Malignant Mesothelioma"],"prefix":"10.3389","volume":"11","author":[{"given":"Zhenying","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongjian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific Clues for Prevention, Diagnosis, and Therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.02.75","article-title":"New Concepts in the Treatment of Malignant Pleural Mesothelioma","volume":"10","author":"Lapidot","year":"2018","journal-title":"J Thorac Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.188","article-title":"Genomic Profiling of Malignant Peritoneal Mesothelioma Reveals Recurrent Alterations in Epigenetic Regulatory Genes BAP1, SETD2, and DDX3X","volume":"30","author":"Joseph","year":"2017","journal-title":"Mod Pathol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.humpath.2016.04.015","article-title":"Genomic Copy Number Alterations in 33 Malignant Peritoneal Mesothelioma Analyzed by Comparative Genomic Hybridization Array","volume":"55","author":"Chirac","year":"2016","journal-title":"Hum Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202465","article-title":"Comparison of Genomic Abnormality in Malignant Mesothelioma by the Site of Origin","volume":"67","author":"Takeda","year":"2014","journal-title":"J Clin Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.544789","article-title":"Tumor Microenvironment-Associated Immune-Related Genes for the Prognosis of Malignant Pleural Mesothelioma","volume":"10","author":"Xu","year":"2020","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3390\/cancers11101502","article-title":"Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma","volume":"11","author":"Xu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)62492-3","article-title":"Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling","volume":"166","author":"Gordon","year":"2005","journal-title":"Am J Pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e10612","DOI":"10.1371\/journal.pone.0010612","article-title":"Second Generation Sequencing of the Mesothelioma Tumor Genome","volume":"5","author":"Bueno","year":"2010","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.12.025","article-title":"Splicing Modulation as Novel Therapeutic Strategy Against Diffuse Malignant Peritoneal Mesothelioma","volume":"39","author":"Sciarrillo","year":"2019","journal-title":"EBioMedicine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"29\u201349","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach","volume":"15","author":"Nicholson","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.42","article-title":"Novel Insights Into Mesothelioma Biology and Implications for Therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5487","article-title":"Association of Asbestos Exposure With Malignant Mesothelioma Incidence in Eastern China","volume":"3","author":"Mao","year":"2017","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.12.006","article-title":"Improving the Accuracy of Mesothelioma Diagnosis in China","volume":"12","author":"Guo","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus Report of the 2015 Weinman International Conference on Mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.21037\/tlcr.2018.08.03","article-title":"Update on the Management of Malignant Peritoneal Mesothelioma","volume":"7","author":"Sugarbaker","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-020-01305-3","article-title":"Targeting AURKA in Cancer: Molecular Mechanisms and Opportunities for Cancer Therapy","volume":"20","author":"Du","year":"2021","journal-title":"Mol Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00635-6","article-title":"Aurora Kinase A, a Synthetic Lethal Target for Precision Cancer Medicine","volume":"53","author":"Mou","year":"2021","journal-title":"Exp Mol Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1021\/jm1000198","article-title":"Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification","volume":"53","author":"Coumar","year":"2010","journal-title":"J Med Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.5806","article-title":"A Novel Aurora-A Inhibitor, BPR1K0609S1, Sensitizes Colorectal Tumor Cells to 5-Fluorofracil (5-FU) Treatment","volume":"9","author":"Shionome","year":"2013","journal-title":"Int J Biol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0529","article-title":"Aurora A\u2013selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy","volume":"18","author":"Du","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4161\/cc.11.4.19323","article-title":"The Induction of Polyploidy or Apoptosis by the Aurora A Kinase Inhibitor MK8745 Is P53-Dependent","volume":"11","author":"Nair","year":"2012","journal-title":"Cell Cycle"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1371\/journal.pone.0055457","article-title":"Integrity of P53 Associated Pathways Determines Induction of Apoptosis of Tumor Cells Resistant to Aurora-A Kinase Inhibitors","volume":"8","author":"Shionome","year":"2013","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4110\/in.2017.17.2.110","article-title":"Characterization of the Indirubin Derivative LDD970 as a Small Molecule Aurora Kinase a Inhibitor in Human Colorectal Cancer Cells","volume":"17","author":"Ndolo","year":"2017","journal-title":"Immune Netw"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.450","article-title":"Paclitaxel and CYC3, an Aurora Kinase A Inhibitor, Synergise in Pancreatic Cancer Cells But Not Bone Marrow Precursor Cells","volume":"107","author":"Lin","year":"2012","journal-title":"Br J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1158\/1535-7163.MCT-13-1029","article-title":"A Novel Small Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor-Initiating Cells and Overcomes Drug Resistance","volume":"13","author":"Zheng","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","article-title":"Phase Ii Study of Alisertib, a Selective Aurora a Kinase Inhibitor, in Relapsed and Refractory Aggressive B- And T-Cell non-Hodgkin Lymphomas","volume":"32","author":"Friedberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized Phase III Study of Alisertib or Investigator\u2019s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma","volume":"37","author":"O\u2019Connor","year":"2019","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.06.040","article-title":"Phase II Study of MLN8237 (Alisertib), an Investigational Aurora A Kinase Inhibitor, in Patients With Platinum-Resistant or -Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma","volume":"127","author":"Matulonis","year":"2012","journal-title":"Gynecol Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1470-2045(15)70051-3","article-title":"Safety and Activity of Alisertib, an Investigational Aurora Kinase A Inhibitor, in Patients With Breast Cancer, Small-Cell Lung Cancer, non-Small-Cell Lung Cancer, Head and Neck Squamous-Cell Carcinoma, and Gastro-Oesophageal Adenocarcinoma: A Five-Arm Phase 2 Study","volume":"16","author":"Melichar","year":"2015","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912.A","article-title":"A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients With Castration Resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30203-0","article-title":"Alisertib Plus Induction Chemotherapy in Previously Untreated Patients With High-Risk, Acute Myeloid Leukaemia: A Single-Arm, Phase 2 Trial","volume":"7","author":"Brunner","year":"2020","journal-title":"Lancet Haematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0286","article-title":"Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib Plus Rituximab or Rituximab\/Vincristine in Relapsed\/Refractory Aggressive B-Cell Lymphoma","volume":"24","author":"Kelly","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.4889","article-title":"Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A Nant (New Approaches to Neuroblastoma Therapy) Trial","volume":"34","author":"DuBois","year":"2016","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1381","article-title":"Phase II Trial of Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma","volume":"24","author":"DuBois","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0264-7.Aurora","article-title":"Aurora Kinase A Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer","volume":"25","author":"Shah","year":"2019","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3397","article-title":"Aurora A Inhibition Eliminates Myeloid Cell- Mediated Immunosuppression and Enhances the Efficacy of Anti-PD-L1 Therapy in Breast Cancer","volume":"79","author":"Yin","year":"2019","journal-title":"Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.789244\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T05:30:13Z","timestamp":1638941413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.789244\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,8]]},"references-count":37,"alternative-id":["10.3389\/fonc.2021.789244"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.789244","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,12,8]]},"article-number":"789244"}}